Treatment results of modified BFM protocol in pediatric high-risk Burkitt lymphoma

Vural S., Genc D. B., Kebudi R., Dogan O., Karaman S.

TURKISH JOURNAL OF PEDIATRICS, cilt.63, sa.4, ss.639-647, 2021 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 63 Sayı: 4
  • Basım Tarihi: 2021
  • Doi Numarası: 10.24953/turkjped.2021.04.011
  • Dergi Adı: TURKISH JOURNAL OF PEDIATRICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.639-647
  • Anahtar Kelimeler: Burkitt lymphoma, BFM, methotrexate, NON-HODGKIN-LYMPHOMA, HIGH-DOSE METHOTREXATE, B-CELL MALIGNANCIES, CHILDREN, CHEMOTHERAPY, ADOLESCENTS, EXPERIENCE, CHILDHOOD, THERAPY, INVOLVEMENT
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background. Chemotherapy with high dose methotrexate is the mainstay of treatment for Burkitt lymphoma (BL), especially to manage central nervous system (CNS) disease. However, methotrexate administration requires close drug level monitoring for appropriate folinic acid rescue, which might not be readily available in all centers. In this study, we assessed the long-term treatment outcomes of a modified Non-Hodgkin lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM) 90 regimen in pediatric high-risk BL without CNS involvement.